Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (2999)	11/25/1997 11:06:00 PM
From: Izzy	Read Replies (1) \| Respond to of 6136

John, the links in your last post were very good. I am particularly intrigued by the Murex Technology LiPA HIV-1 RT (reverse transcriptase) test, which uses multiple probe DNA testing of the HIV gene. This apparently enables detection of wild type and drug-induced strains associated with AZT, ddI, ddC, 3TC, and "1592U89" resistance. The company makes a statement that, "prior to treatment, HIV patients may already be resistant to some HIV drugs if they were infected with a strain of HIV that had been previously been treated with antiviral drugs"---fascinating statement. Any comments? Dr. Oliver, do you use such testing in your practice?